Using Amadorins to improve Alzheimer's disease and related dementias
Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD)
This study is looking at a new medication called Amadorin that might help people with Alzheimer's and similar conditions by reducing harmful substances in the brain, and if it works, it could help improve thinking skills and slow down the disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Praetego, INC. NIH-funded |
| Lab location | 1 site (Durham, UNITED STATES) |
| Project ID | NIH-10704225 on NIH RePORTER |
What this research studies
This research investigates a new drug candidate called Amadorin, which aims to inhibit the formation of harmful compounds associated with Alzheimer's disease and related dementias. The approach focuses on reducing oxidative stress and preventing neuronal damage by targeting advanced glycation end products (AGEs) and metal ions that contribute to disease progression. Patients may benefit from this treatment if it proves effective in clinical trials, potentially improving cognitive function and slowing disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias, particularly those in the early stages of the disease.
Not a fit: Patients with advanced Alzheimer's disease or those who do not have a diagnosis of Alzheimer's or related dementias may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that slows the progression of Alzheimer's disease and improves cognitive function in affected individuals.
How similar studies have performed: Previous research has shown promise in using similar antioxidant approaches to mitigate cognitive decline in animal models, suggesting potential for success in human applications.
Where this research is happening
Durham, UNITED STATES
- Praetego, INC. — Durham, United States (Active)
Researchers
- Principal investigator: Khalifah, Raja G — Praetego, INC.
- Study coordinator: Khalifah, Raja G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.